Skip to main content

The independent medical news service

21-02-2020 | Oncology | News | Article

Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

Patients with metastatic papillary renal cell carcinoma are likely to benefit from the durvalumab–savolitinib combination, show findings from the 1-year follow-up of the CALYPSO trial.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

08-01-2020 | Oncology | News | Article

PD-1 inhibition may result in better solid tumor survival than PD-L1 inhibition

Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.

07-01-2020 | Oncology | News | Article

Tumor microenvironment changes implicated in clear cell RCC obesity paradox

Tumors from obese patients with clear cell renal cell carcinoma have higher angiogenesis scores than those from normal-weight patients, as well as differences in the tumor microenvironment, US researchers report.

13-12-2019 | Oncology | News | Article

Sarcopenia could predict the immune-related toxicity risk associated with nivolumab

Sarcopenia in cancer patients taking nivolumab is associated with an increased risk for immune-related acute limiting toxicity, independent of plasma nivolumab concentrations, study results suggest.

21-11-2019 | Oncology | News | Article

Data support immunotherapy combination for RCC with variant histology, sarcomatoid features

A meaningful proportion of patients with advanced renal cell carcinoma with variant histology or sarcomatoid differentiation respond to the immunotherapy combination of atezolizumab and bevacizumab without experiencing severe toxicity, phase II study data show.

22-10-2019 | Oncology | News | Article

Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

Image Credits